| Prev Close | 34.95 |
| Open | 34.90 |
| Day Low/High | 33.70 / 35.00 |
| 52 Wk Low/High | 23.30 / 39.20 |
| Volume | 144.32K |
| Avg Volume | 380.90K |
| Exchange | NASDAQ |
| Shares Outstanding | 32.73M |
| Market Cap | 1.13B |
| EPS | -0.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 1,318,658 share increase in total short interest for BioTelemetry Inc , to 3,622,167, an increase of 57.25% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Investors in BioTelemetry Inc saw new options begin trading this week, for the August 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
In trading on Monday, shares of BioTelemetry Inc crossed above their 200 day moving average of $30.75, changing hands as high as $30.85 per share. BioTelemetry Inc shares are currently trading up about 2.5% on the day.
Investors in BioTelemetry Inc saw new options become available this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BEAT options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
First to Market Alliance Increases Precision and Specificity while Reducing Cost
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
In trading on Tuesday, shares of BioTelemetry Inc crossed below their 200 day moving average of $30.11, changing hands as low as $29.85 per share. BioTelemetry Inc shares are currently trading off about 1.3% on the day.
Jim Cramer is bullish on Delta Air Lines, BioTelemetry, TransUnion, Amgen and Littelfuse.
Jim Cramer says there's a case to be made for underpricing, even in this market.
Joe Capper, president and CEO of BioTelemetry, tells Jim Cramer that the connected health market is relatively new and no one really knows just how big it could be.
Jim Cramer says that with the exception of the department stores and the oils, a case can be made for almost anything in this market.
Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.
Cramer takes a closer look at heart-monitor company BioTelemetry.
The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 850,459 share decrease in total short interest for BioTelemetry Inc , to 1,674,666, a decrease of 33.68% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
In recent trading, shares of BioTelemetry Inc have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
VIX climbs while gold and bonds catch a bid.
In recent trading, shares of BioTelemetry Inc have crossed above the average analyst 12-month target price of $33.00, changing hands for $34.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Deal Solidifies BioTelemetry's Leadership Position in Remote Cardiac Monitoring
In recent trading, shares of BioTelemetry Inc have crossed above the average analyst 12-month target price of $28.67, changing hands for $29.65/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
